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Metastatic melanoma is a very aggressive form of cancer in both humans and dogs.
Dogs primarily develop oral melanoma of mucosal origin. Although oral melanoma
in humans is rare, both diseases are highly aggressive with frequent metastases.
This disease represents a “One Health” opportunity to improve molecular and
mechanistic understanding of melanoma progression. Accumulating evidence suggests
that cyclooxygenase-2 (COX-2) may play a critical role in the malignant behaviour of
melanoma. In this study we analysed 85 histologically confirmed melanomas from
canine patients and showed that COX-2 is overexpressed in both oral and cutaneous
melanomas and that COX-2 expression correlates with established markers of poor
prognosis. To determine the role of COX-2 in melanoma we developed two melanoma
cell lines with stable integration of an inducible doxycycline-regulated expression vector
containing a COX-2 targeted micro-RNA (miRNA). Using this system, we showed that
cellular proliferation, migration and invasion are COX-2 dependent, establishing a direct
relationship between COX-2 expression and malignant behaviour in canine melanoma.
We have also developed a powerful molecular tool to aid further dissection of the
mechanisms by which COX-2 regulates melanoma progression.
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INTRODUCTION
In humans, melanoma is one of the most aggressive types of cancer, every year killing ∼50,000
people worldwide (1). Cutaneous forms represent the most common cases and are responsible
for 65% of all skin malignancy-related deaths (2). Melanomas of the oral cavity are rarer
but are associated with aggressive behaviour, including a tendency to repeated relapse and to
metastasise, and poor patient outcomes (3). In contrast, the majority of melanomas forming
in dogs are of mucosal origin, and most commonly seen in Scottish terriers, golden retrievers,
poodles and dachshunds indicating a genetic predisposition to this disease. Canine oral melanoma
is very aggressive and highly metastatic, with frequent metastases to local lymph nodes and
lungs (4). Therefore, there is potential to adopt a “One Health” approach to improve molecular
and mechanistic understanding of melanoma progression. Accumulating evidence suggests that
cyclooxygenase-2 (COX-2) expression may be considered as a prognostic biomarker and as a
potential therapeutic target in both humanmelanoma (5, 6) and canine melanocytic neoplasms (7).
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COX-2, also known as prostaglandin-endoperoxide synthase
2 (PTGS2), is an inducible form of the rate-limiting enzyme in
the metabolic conversion of arachidonic acid to prostaglandins,
including prostaglandin E2 (PGE2), a significant mediator
of inflammation and angiogenesis. Previously, COX-2
overexpression has been described in multiple human cancers
including skin, bone, oesophageal, breast, lung, pancreatic, colon,
cervical, prostate and bladder cancer, and is inversely associated
with patient survival (8). At the molecular level the COX-2/PGE2
axis modulates a number of signal transduction pathways in
human cancer cell lines that affect tumour cell proliferation,
apoptosis, immune evasion, angiogenesis, cellular adhesion,
differentiation and invasion (9). In canine osteosarcoma, we
have previously shown that COX-2 expression is 141-fold higher
in the cancer stem cell population compared to the non-cancer
stem cell population, and that COX-2 plays a major role in
tumour initiation (10). Consistently, inhibition of COX-2 with
either non-steroidal anti-inflammatory drugs (NSAIDs) or with
specific COX-2 inhibitors (COXIBs) can reduce the mortality
of several types of cancer (11) and can switch the immune
response from a tumour-promoting profile to a tumour-
destructive one, re-ordering the tumour microenvironment (12).
However, despite ample epidemiological evidence supporting an
inverse relationship between NSAID use and the incidence and
progression of cancer the clinical application of these drugs for
cancer prevention remains controversial. NSAIDs and COXIBs
have been shown to have off-target effects and to supress the
biosynthesis of other physiologically relevant prostaglandins that
are associated with the adverse side-effects of these drugs on the
GI tract and cardiovascular system, including elevated risk of
myocardial infarction and stroke (13, 14). We have previously
shown that mavacoxib (TrocoxilTM), a clinically relevant COXIB
in veterinary medicine, which is currently licenced to treat
pain and inflammation in canine osteosarcoma, can exert
anti-tumourigenic effects on a panel of canine cancer cell lines
with low COX-2 expression indicating that this drug may act in
a COX-2 independent manner (15).
In the context of canine melanoma, the exact role of COX-2
in the progression of the disease has not been fully elucidated.
Previous studies have examined the association between COX-
2 expression and prognostic factors, such as Ki-67 proliferation
index and survival time after diagnosis, in melanocytic tumours
and concluded that COX-2 may be associated with malignancy
and may be a potential prognostic marker (7, 16, 17). In vitro,
COX-2 inhibition by celecoxib in two canine melanoma cell lines
has been shown to supress cell growth and have anti-tumour
effects (18). One of the limitations of veterinary research is a
lack of molecular tools to dissect the contribution of COX-2 to
tumour progression. A model system in which reversible loss of
COX-2 function could be controlled in space and time would
be of significant value. In this study we have correlated the
expression level of COX-2 in samples from canine patients with
establishedmarkers linked to poor prognosis, and we describe the
development of two melanoma cell lines with stable integration
of a doxycycline-regulated expression vector containing a COX-
2 targeted micro-RNA (miRNA), to enable us to reversibly
suppress endogenous COX-2 gene expression. We utilised this
system to show that COX-2 is an essential driver of cellular
proliferation, migration and invasion of canine melanoma cells.
MATERIALS AND METHODS
Retrospective Case Material and
Histologic Classification
Eighty-five cases from canine patients in which melanoma was
diagnosed were retrieved from the archive of the Comparative
Pathology Laboratory, Department of Pathology, Universidade
Federal de Minas Gerais, Belo Horizonte, Brazil. Informed
client consent was obtained for all patient samples used in this
study. Of these, 29 cases were oral melanomas and 56 were
cutaneous melanomas. To confirm the primary diagnosis each
sample was re-examined independently by two pathologists (E.F.
and T.S.) according to the criteria, established by the World
Health Organisation (WHO), of the International Histological
Classification of Tumours of Domestic Animals (19), using
a Olympus BX41 microscope. Formalin-fixed and paraffin-
embedded (FFPE) tissues were cut into sections (4µm) using
a Leica RM2245 microtome. Deparaffinised samples were used
for Hematoxylin and Eosin (H&E) staining. Clinicopathological
features were evaluated: (1) presence of ulceration; (2) degree
of pigmentation; (3) morphology of neoplastic cells (spindle,
epithelioid or mixed); (4) mitotic index (MI); and (5) tumoural
vascular invasion. The MI was determined by counting all the
mitoses within 10 random, non-overlapping high-power fields
(HPFs) (×400), FN 22/40x objective (2.37 mm2) (20). A MI
was attributed according to the number of mitoses: low MI (<4
mitoses per 10 HPFs); high MI (≥4 mitoses per HPFs) (21).
The degree of pigmentation was estimated using a subjective
scale from 0 (no pigmentation), 1 (pigmentation in 25% of
neoplastic cells), 2 (pigmentation in 25–50% of neoplastic cells)
to 3 (pigmentation in >50% of neoplastic cells).
Immunohistochemical Analysis
FFPE tissue samples were cut into 4µm sections and processed
for immunohistochemical (IHC) analysis of S-100, melan-
A, PNL-2, COX-2 and Ki-67. All immunostainings utilised
the streptavidin-biotin-peroxidase complex method with a
commercial detection anti-mouse/anti-rabbit system (Novolink
Polymer Detection Sistem; Leica Biosystems, Newcastle upon
Tyne, UK) according the manufacturer’s instructions. Antigen
retrieval was performed by Pascal R© in citrate buffer pH 6.0
(DakoCytomation Target Retrieval Solution) at 125◦C for 2min,
followed immediately by 20min at room temperature (RT). All
sections were incubated with the primary specific antibody: S-100
(1:100 dilution, Clone S100, Dako, Glostrup, Denmark), melan-
A (1:100 dilution, Clone A103, Dako, Glostrup, Denmark),
Melanoma Antigen (1:100 dilution, Clone PNL-2, Santa Cruz
Biotechnology, Dallas, Texas, USA), COX-2 (1:80 dilution, Clone
SP21, Thermo Fisher Scientific, Walthan, MA, USA) or Ki-67
(1:50 dilution, Clone MIB-1, Dako, Glostrup, Denmark) for 18 h
at 4◦C. The antibody reactions were visualised with chromogen
3,3′ -diaminobenzidine tetrachloride (DAB) diluent (Dako, Code
K3468), incubated for 3min at RT. The samples were washed 3x
times in distilled water for 5min at RT, then counterstained with
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Giemsa for 30min at RT, dehydrated and mounted (22). Sections
treated with isotype-matched primary antibodies mouse anti-
human IgG were used as negative controls and this study also
included adequate positive controls: canine mammary tumour
for COX-2; and canine epidermis for melan-A, PNL-2, and Ki-
67. Images were captured on BX41 Olympus microscope. A
subjective scale was then used to establish the degree of positive
staining for S-100, melan-A and PNL-2 (23, 24). For COX-2
staining a distribution score and intensity were multiplied to
obtain a total score, which ranged from 0 to 12. Distribution
was estimated as the percentage of positive cells in 10 HPFs
(x400): 0 (absent); 1 (< 10% stained cells); 2 (10–30% stained
cells); 3 (>30–60% stained cells); and 4 (>60% stained cells).
For staining intensity: 0 (absent); 1 (weak); 2 (moderate); and 3
(strong). The samples with a final score 0–5 were considered to
have COX-2 low expression, and samples with a score of 6–12
were considered to have high COX-2 expression (24). The Ki-
67 index was evaluated by counting 500 tumour cells within a
microscopic grid at high magnification (×400) and the index was
expressed as a percentage.
RNA Extraction and Real-Time
Quantitative PCR From FFPE Samples
RNA was extracted from FFPE tissue samples using the
RecoverAllTM Total Nucleic Acid Isolation Kit (Thermo Fisher
Scientific, Walthan, MA, USA, Code AM1975), according to
the manufacturer’s instructions. Extracted RNAs were quantified
and 260/280 nm absorbance determined by NanoDrop Nucleic
Acid Quantification (Thermo Fisher Scientific, Walthan, MA,
USA). Total RNA was reverse transcribed using the M-MLV
kit (Invitrogen, CA, USA, Code 280250-13) according to the
manufacturer’s instructions. The RNA integrity was evaluated by
conventional RT-PCR analysis with the amplification of a 120
base pair fragment of the dog GAPDH reference gene, using the
forward 5′-TTCCACGGCACAGTCAAG-3 and reverse 5′-ACT
CAGCACCAGCATCAC-3′ primers. For quantitative real-time
PCR 90 ng of cDNA was used in a final qPCR reaction with
SYBR Green R© PCR Master Mix Kit according to manufacturer’s
instructions (Invitrogen, CA, USA) and ABI PRISM R© 7500
Sequence Detection System (Carlsbad, CA, USA). For the RT-
qPCR the cycling conditions used were: (stage 1) 1 cycle of 50◦C
for 2min; (stage 2) 1 cycle at 95◦C for 10min.; (stage 3) 40
cycles of 95◦C for 15 s then 55◦C for 1min. After completion
of the amplification reaction, melt-curve analysis was carried
out at 95◦C for 15 s to produce a dissociation curve. Relative
gene expression levels were obtained by normalisation to the
expression level of a housekeeping gene (HPRT) (25). Primer
sequences are shown in Table 1.
Cell Culture
The panel of canine melanoma cell lines used in this study
included CMGD2, CMGD-5, CML-10 and TLM1 (Kerafast,
Boston, MA, USA), cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% foetal bovine
serum, 100µg/ml streptomycin (ThermoFisher Scientific) and
5% HEPES (ThermoFisher Scientific). Canine transitional cell
carcinoma of the urinary bladder cell line (K9TCC) (a
TABLE 1 | Primer sequences for the amplification of qRT-PCR products from
canine FFPE tissue samples.
Gene Forward primer (5′-3′) Reverse Primer (5′-3′)
COX-2 CCTGACACCTTGCAAATAG ATTCCACAAACTGGGTAAGG
HPRT CCTTGGTCAAGGAGCATAATC GTCAAGGGCATATCCTACAAC
TABLE 2 | Primer sequences for the amplification of qRT-PCR products from
canine cell lines.
Gene Forward primer (5′-3′) Reverse Primer (5′-3′)
COX-2 GCCCTATACATCATTCGAAGAAC CACCATAAAGGGCCTCCAA
GAPDH GGGAAGATGTGGCGTGAC GAAGGCCATGCCAGTGAG
kind gift from Deborah Knapp and Jane Stewart, Purdue
University) was grown in DMEM/F-12 (ThermoFisher Scientific)
containing HEPES and L-glutamine and supplemented with
10% FBS and 100µg/mL penicillin/streptomycin. All cells
were maintained at 37◦C in a humidified atmosphere with
5% CO2.
Real-Time Quantitative PCR
RNA was extracted from cells using the RNeasy Kit (Qiagen,
CA USA) according to the manufacturer’s instructions. Real-
time PCR was executed using 50 ng of amplified RNA and the
Stratagene Mx3000p qPCR system (Aligent, CA, USA), using
the Platinum R© SYBR R© Green qPCR SuperMix-UDG according
to manufacturer’s instructions (Invitrogen, CA, USA). For the
RT-qPCR the cycling conditions used were: (stage 1) 1 cycle of
95◦C for 2min; (stage 2) 40 cycles of 95◦C for 5 s followed by
60◦C for 10 s. After completion of the amplification reaction,
melt-curve analysis was carried out according to the instrument’s
instructions. Relative gene expression levels of COX-2 were
obtained by normalisation to the expression level of a
housekeeping gene (GAPDH) (25). Primer sequences are shown
in Table 2.
Construction of a Canine Inducible COX-2
miRNA Expression Vector
The generation of inducible vectors expressing COX-2 miRNAs
were constructed using custom designed complementary
canine COX2 oligos (Invitrogen’s RNAi Designer, USA), with
each containing 4 nucleotide overhangs necessary for directional
cloning. The complementary COX2 oligos were annealed and the
resulting double-stranded oligo was cloned into pcDNATM6.2-
GW/EmGFP-miR vector (pcDNAGFPmiRNACOX2-346)
according to the Block-iT TM PolII miR RNAi expression
vector kit manual (Invitrogen). A negative control plasmid,
pcDNATM6.2-GW/EmGFP-miRneg (included in the kit),
containing a miRNA insert predicted not to target any known
vertebrate gene, was also used for the subsequent cloning steps.
Custom designed canine double-strand COX2-346 oligo,
with 4 nucleotide overhangs (bold), cloned into pcDNATM6.2-
GW/EmGFP-miR vector:
Frontiers in Veterinary Science | www.frontiersin.org 3 August 2021 | Volume 8 | Article 633170





The pcDNAGFPmiRNACOX2-346 and pcDNATM6.2-
GW/EmGFP-miRNeg vectors are Gateway R© compatible due
to the presence of attB sites flanking the COX-2 miRNA insert
and can be transferred to other Gateway R© adapted destination
vectors that contain attR sites. After removal of emGFP,
canine COX-2 miRNAs and miRNeg expression cassettes were
transferred to the pTRIPZdest destination vector (a kind gift
from Dr Peter Hohenstein, Roslin Institute) using the rapid
Invitrogen BP/LR protocol (Invitrogen). The destination vector
pTRIPZdest is a lentiviral inducible vector engineered to be Tet-
On. Following transfer of the COX2miRNA in the pTRIPZdest,
the tetracycline response element (TRE), placed upstream of a
minimal promoter, will drive the co-expression of a TurboRFP
reporter gene and the COX2miRNA if the transactivator (rtTA3)
binds to TRE which only occurs in the presence of doxycycline
(DOX). The induced expression of TurboRFP allows tracking of
transfection efficiency, TRE promoter activity and COX2miRNA
expression. The pTRIPZdestmiRCOX2 vectors contain the
puromycin resistance gene (puro) which allows for puromycin
selection of any mammalian cell lines that are stably transfected
with the vectors.
Transfection of Inducible COX-2 miRNA
Expression Vector and the Generation of
Stable Cell Lines
CMGD-2, CMGD-5, CML-10 and TLM-1 cells were seeded at 2
× 105 in 6-well plates and incubated for 24 h. At 80% confluency
cells were transfected with 2.5 µg DNA (pTRIPZdestmiRCOX2-
346 expression vector) per well at a final concentration of 1
µg/µl using 12.5 µl (CMGD-2 and CMGD-5), 9 µl (CLM-10)
and 6 µl (TLM-1) Lipofectamine R© 2000 reagent (ThermoFisher
Scientific, USA) according to the manufacturer’s instructions.
pTRIPZdestmiRNeg plasmid negative control plasmid was used
as a negative control in subsequent experiments. To establish
stable transfection, cells were exposed to 2µg/ml of puromycin
48 h post-transfection. After 10–14 days of selection, puromycin-
resistant colonies were pooled and expanded.
Proliferation Assay
Transfected cells were seeded in triplicate in opaque 96-well
plates (Corning, CA, USA) at 2,000 cells/well. Cells were
incubated 37◦C, 5% CO2 and cell viability was assayed 48 h
later using the CellTiterGlo R© Luminescent Cell Viability Assay
(Promega, Madison, USA, Code G7570) according to the
manufacturer’s instructions. Luminescence was recorded using a
Viktor3 luminometer (PerkinElmer, Massachusetts, USA). Data
was averaged, and then normalised against the average signal of
untreated/negative control treated samples.
Colony Formation Assay
Transfected cells were seeded at 500 cells/10 cm plate and
immediately treated with the indicated dose of DOX. Plates were
incubated until colonies were visible at 37◦C in a humidified
CO2 incubator. Growth media was changed approximately once
a week. The colonies were fixed by incubating for 5min with ice-
cold methanol at RT. Colonies were air dried and then stained
with Giemsa (Invitrogen, Paisley, UK) for 20min at RT. The total
number of colonies were counted.
Invasion Assay
Invasion assays were performed using transwell system with
two compartments separated by 8µm pore polycarbonate
philtres coated with Matrigel (BD Biosciences). In the upper
compartment ∼2 × 104 cells were seeded in serum-free media,
and the lower compartment contained media spiked with 5%
FBS. Cells were allowed to transmigrate for 24 h. Non-migrated
cells on the upper side of the transwell were removed. Cells on the
underside of the transwell were fixed with methanol and stained
with 0.1% crystal violet. These represented cells that hadmigrated
through the philtre. Ten different fields (x200) were counted in
triplicate experiments.
Cellular Migration Assay
Transfected cells were incubated at 37◦C in humidified 5%
CO2 incubator grown until 80–90% confluent in 6-well plates.
A scratch was made in the confluent monolayer of cells with
a pipette tip. The gap was visualised using the Axiovert 40
CFL microscope coupled with an AxioCAM HRm camera (Carl
Zeiss Ltd, Cambridge, UK) and measured at 6 points/gap and
an average taken. Measurements were made over the indicated
time course. Scratch width was converted to “relative migration
distance” of cells, where the distance is a percentage of the initial
wound width.
Statistical Analysis
Data were expressed as a mean ± S.D. Statistical analysis
was performed with GraphPad Prism version 5.0 for Windows
(GraphPad software, CA USA) using Spearman’s correlation for
non-parametric analysis test, analysis of variance and Student’s t-
test or mann-whitney test. The criterion for significance was p <
0.05 for all comparisons.
RESULTS
Immunohistochemical Analysis of Canine
Melanoma Samples
A total of 85melanoma tumours (29 orals and 56 cutaneous) were
included in this study and classified accordingly: 23 spindle cell,
53 epithelioid cell and nine mixed. High pigmentation level is
inversely correlated with overall survival time in human patients
and is an important marker of the disease (26). Here the degree
of pigmentation was estimated using a subjective scale from 0 (no
pigmentation) to 3 (pigmentation in>50% of neoplastic cells). Of
the 85 samples: 20 had no pigmentation; 42 scored 1; 7 scored 2;
and 16 scored 3. Regarding the mitotic index (MI), 74 cases were
evaluated (24 orals and 50 cutaneous), of those, 14 oral and 20
cutaneous melanomas had a high MI (≥4 mitoses per 10 HPF)
(Table 3). The MI could not be evaluated on 11 other cases due
to high pigmentation.
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TABLE 3 | Clinicopathological parameters of the oral and cutaneous melanomas.
Oral Cutaneous
Histological type
Epithelioid cells 23 30
Spindle cells 3 20
Mixed 3 6
Pigmentation
0 (no pigmentation) 12 8
1 (25% of cells) 12 30
2 (25–50%) 1 6
3 (>50%) 4 12
Mitotic index
<4 mitoses 10 30
≥4 mitosis 14 20
TABLE 4 | Immunohistochemical positivity of oral and cutaneous melanomas by
S-100, melan-A, PNL-2, and COX-2 antibodies.
Molecular markers Oral Cutaneous
S-100 100% (29/29) 100% (56/56)
melan-A 93% (27/29) 100% (56/56)
PNL-2 100% (12/12) 100% (8/8)
COX-2
Score 0 7% (2/29) 12% (7/56)
Score 1–5 59% (17/29) 45% (25/56)
Score 6–12 34% (10/29) 43% (24/56)
The immunoreactivity for S-100, melan-A, and PNL-2 was
observed as brown cytoplasmic staining. All samples were
positive for S-100 protein and PNL-2, and 75 of 85 were
positive for melan-A. Of the 10 cases that were negative for
melan-A the diagnosis was confirmed by positive staining for
PNL-2 (Table 4). Overall, a high COX-2 expression revealed a
statistically significant correlation with Ki-67 (p= 0.03), however
when oral and skinmelanomas were analysed independently only
the skin tumours presented statistical significance (p = 0.01)
(representative images of Ki-67, melan-A, PNL-2 and COX-2
staining are shown in Figure 1).
We found that COX-2 was located in the cellular membrane,
cytoplasm, and nuclear membrane in a diffuse and homogeneous
pattern. In the primary tumour the labelling intensity of
COX-2 was comparable to that of neoplastic intravascular
emboli, however, the extension of COX-2 staining in neoplastic
intravascular emboli was always diffuse. These results confirmed
that COX-2 was expressed, at some degree, in 90% of all tumours
examined (Figures 1E,F) and that 34 of 85 of these tumours had a
combined distribution and intensity score of 6–12. Of the 29 oral
melanomas, 10 showed a COX-2 score of 6–12, whereas 24 of 56
of cutaneous melanomas scored 6–12 (Table 4).
The high COX-2 expression revealed a statistically significant
correlation with both oral and cutaneous tumours with Ki-67
(r = 0.45; p = 0.03), MI (r = 0.49; p < 0.001), lymphatic
invasion (r = 0.41; p = 0.04) and the histological type of tumour
(epithelioid and mixed) (r = 0.51; p = 0.003). In the cutaneous
tumours the presence of skin ulceration (r = 0.49; p = 0.02) was
also statistically correlated with high COX-2 levels. Thus, these
results suggest that high COX-2 protein levels could be associated
clinicopathological aggressiveness parameters. To correlate this
data to COX-2 gene expression we isolated RNA from the FFPE
samples and determined COX-2 gene expression by qRT-PCR.
The samples were divided according to the previous IHC results
into low and high COX-2 protein levels. The gene expression
revealed a statistically significant inverse correlation with the
COX-2 protein expression (r = 0.64; p= 0.0008) (Figure 1G).
Construction of an Inducible COX-2 miRNA
Expression Vector
Artificial miRNAs were engineered to have 100% homology to
the target COX-2 sequence and result in cleavage. To test the
candidate miRNAs for suppression of COX-2 expression, three
canine COX-2miRNA vectors were transiently transfected by
lipofection into a canine bladder cancer cell line (K9TCC) that
highly expresses COX-2. The vector contains a CMV promoter-
driven puromycin resistance gene and a green fluorescent
protein (GFP) gene to select and identify transfected cells.
EmGFP/COX-2miRNA and EmGFP/miRNeg expressing cells
were sorted 48 h post-transfection by fluorescence-activated
cell sorting (FACS). COX-2 down-regulation was assessed by
qRT-PCR using the comparative CT (211CT) method. The
pcDNAemGFPmiRCOX2 vectors are Gateway R© compatible
(Figure 2A(i)). After removal of emGFP, canine COX-2miRNAs
and miRNeg expression cassettes were transferred to the
pTRIPZdest destination vector (a kind gift from Dr Peter
Hohenstein, Roslin Institute) (Figure 2A(ii)). This is an inducible
system activated by DOX. COX-2 down-regulation was assessed
by qRT-PCR in K9TCC inducible clones grown over a week in
DOX (2µg/ml) (Data not shown).
Generation and Characterisation of
Melanoma Cell Lines Stably Expressing an
Inducible COX-2 miRNA Vector
The basal gene expression of COX-2 in each cell line was
determined by qRT-PCR. COX-2 expression was highest in
CMGD2, whereas the lowest level COX-2 expression was
detected in CML10 cells (Figure 2B). The CMGD2 and
TLM1 melanoma cell lines were stably transfected with the
pTRIPZdestmiRCOX2-346 vector and control cells with the
pTRIPZdestmiRNeg plasmid. Puromycin was applied 48 h post-
transfection to select for stable expression of the plasmid.
CMGD2 and TLM1 puromycin-resistant colonies were pooled
10–14 days following transfection, expanded and frozen
for subsequent experiments. To test the inducible system,
CMGD2 and TLM1 puromycin-resistant pools expressing
the pTRIPZdestmiRCOX2-346 (miRNACOX2-346) vector or
miRNeg control vector were exposed to 1µg/ml of DOX.
The pTRIPZdestmiRCOX2-346 vector contains a tetracycline-
dependent promoter which in the presence of DOX drives the
expression of the miRNA and the expression of a TurboREP
reporter, allowing assessment of promoter activity. Here
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FIGURE 1 | COX-2 expression in oral and skin melanoma in the dog. (A) Oral, mucosal melanoma, no pigmentation. H&E staining. (B) Skin. Ki-67 staining in the
nucleus of neoplastic cells. DAB staining of chromogen. Giemsa counterstain. (C) Oral. Melan-A staining in the cytoplasm of neoplastic cells. DAB staining of
(Continued)
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FIGURE 1 | chromogen. Giemsa counterstain. (D) Skin. Melanoma Antigen (PNL-2) staining in the cytoplasm of neoplastic cells. DAB staining of chromogen. Giemsa
counterstain. (E) Oral. COX-2 staining, low expression (score 4) in neoplastic cells. DAB staining of chromogen. Giemsa counterstain. (F) Skin. COX-2 staining, high
expression (score 12) in neoplastic cells. DAB staining to chromogen. Giemsa counterstain. All images are objective 40x. Scale bar represents 40µM. (G) Relative
COX-2 mRNA expression comparing IHQ samples with low and high COX-2 immunostaining (p = 0.02*).
TurboRFP expression was assessed by fluorescence microscopy.
We confirmed that COX-2 gene expression was decreased
in CMGD2 cells expressing miRNACOX2-346 +DOX and
TLM1 cells expressing miRNACOX2-346 +DOX compared to
cells expressing the miR negative control (Figure 2C(i) and
(ii), respectively).
Effects of COX-2 Knockdown on Cell
Proliferation
To determine if COX-2 has an effect on cell viability of melanoma
cell lines we used the CMGD2 and TML1 cell lines stably
expressing the miRNACOX2-346 or the miR negative control.
Here we induced knock-down of COX-2 by treating cells with
1µg/ml DOX (+) or water (–) as a vehicle control. Cell viability
was assayed 72 h after treatment. Here we showed that cell
viability is COX-2 dependent in both CMGD2 (Figure 3A(i))
and TML1 cell lines (Figure 3A(ii)). Clonogenic survival analysis,
as a measure of cell reproductive death after treatment, shows
that only cells expressing the miRNACOX2-346 vector and
treated with DOX have a reduction in colony-forming ability
(Figure 3B). Taken together, these results indicate that COX-2
may be an important driver of melanoma cell survival.
Invasiveness and Migration Are COX-2
Dependent
The invasive capacity of CMGD2 and TLM1 cells stably
expressing miRNACOX2-346 was determined using a
Boyden chamber assay. CMGD2 miRNACOX2-346 and
TLM1 miRNACOX2-346 cells treated with 1µg/ml DOX (+)
showed a significant reduction in invasiveness compared to both
the vehicle control and the miRNeg control (Figures 4A,B).
Similarly, we assessed migration potential using a standard
scratch assay and showed that induced silencing of COX-2
reduced the ability of both TML1 (Figure 5) and CMGD2 (data
not shown) to close the wound. These results indicate that
COX-2 enhances the migration and invasion capabilities of
canine melanoma cells.
DISCUSSION
The COX-2 pathway is the evolutionarily conserved master
switch that activates the inflammatory response. Under normal
conditions, acute inflammation is a short-term, self-limited
process activated by an inflammatory stimulus. However,
tumours covet a level of “smouldering” inflammation within
their microenvironment and as such over-expression of COX-
2 is a prominent feature of several human cancers, and has
been associated with tissue re-modelling, angiogenesis, cancer
cell survival, metastasis, and immune evasion (8). In human
melanoma COX-2 expression has been linked to malignant
behaviour. In this study we examined the relationship between
COX-2 expression and canine melanoma. Here we present
evidence that COX-2 is overexpressed in both oral and cutaneous
melanomas and that this is related to the degree of pigmentation,
MI, Ki-67 proliferation index and the expression of validated
melanoma markers including S-100 and melan-A. We also
developed a novel inducible COX-2 miRNA vector to effectively
knock-down COX-2 expression in a panel of canine melanoma
cell lines, and showed that a number of aggressive phenotypes
are COX-2 dependent.
Our data is consistent with the notion that canine melanoma
is an effective model for comparative oncology. Spontaneous
melanocytic neoplasms arise inmany domestic animals including
dogs, cats, horses and pigs. However, malignant melanoma is
more common in the domestic dog than other species and a
majority of cases arise in either the oral cavity or the skin (4).
Canine oral melanomas are highly aggressive and frequently
metastasise, principally to local lymph nodes and lungs, whereas
cutaneous melanomas are most often benign. In contrast to
dogs, cutaneous melanomas are more common in humans, and
melanoma of the oral cavity is extremely rare but exceedingly
aggressive, metastatic and associated with poor patient outcomes
(27). Because of their rareness, accounting for <1% of all
melanomas in humans, there is currently a lack of knowledge
regarding pathogenesis including etiological factors, risk factors
and molecular drivers (28). We propose that there is a significant
opportunity to utilise the dog model to improve molecular and
mechanistic understanding of melanoma progression.
Previously, overexpression of COX-2 has been correlated
with the development and progression of human cutaneous
melanoma (29, 30) and has been proposed as a prognostic
marker. In oral melanoma, COX-2 is highly expressed but
negative in oral nevi indicating that COX-2 is a valuable marker
to distinguish melanocytic lesions of the oral cavity (31), and
elevated COX-2 expression is correlated with poor prognosis
(32). Similarly, in canine melanoma COX-2 levels are related to
Ki-67 proliferation index and survival rate indicating that COX-2
is related to the acquisition of malignancy (7, 16, 33, 34). These
results are consistent with our own findings that are presented
here; where 89% of all tumours (76 of 85) express some degree
of COX-2, with 34% of oral melanomas (10 of 29) and 42%
of cutaneous tumours (24 of 56) expressing the highest level of
combined distribution and intensity. We also show that COX-2
protein level correlates with Ki-67 proliferation rate, MI and the
expression of established melanoma markers.
A mouse model of ovarian cancer has shown a COX-2
gene dosage effect in promoting tumour development, and
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FIGURE 2 | Construction of an inducible COX-2 miRNA expression vector in canine melanoma cell lines. (A) Canine double-stranded COX-2 miRNAs were generated
and cloned into (i) pcDNATM6.2-GW/EmGFP-miR vector (Invitrogen) and transferred to (ii) pTRIPZdest destination vector. (B) Basal expression level of COX-2 in
CMGD2, CMGD5, TLM1, and CML10 canine melanoma cell lines. (C) Validation of inducible COX-2 mi-RNA expression: (i) CMGD2 cells and (ii) TLM1 cells were
transfected with 2.5 µg of the vector or negative control after 24 h cells were treated with 1µg/ml DOX (+) or vehicle control (–) and COX-2 expression was
determined by qRT-PCR. Data shown as fold change relative to miRneg (+) expression (p = 0.03*, p = 0.002**).
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FIGURE 3 | Melanoma cell viability and colony-forming ability is COX-2 dependent. (A) Cell viability of CMGD2 (i) and TLM1 (ii) was determined after transfection with
either miRNACOX2-346 or the miRneg negative control with (+) or without (–) DOX. Cell viability was assayed 48 h after DOX treatment (p = 0.001*, p = 0.003**). (B)
Colony forming ability of CMGD2 (i) and TLM1 (ii) was determined after transfection with either miRNACOX2-346 or the negative control with (+) or without (–) DOX (p
= 0.0001*, p = 0.01**).
interestingly they showed that COX-2 may be important for
tumour initiation whereas progression and malignancy is driven
by COX-1 (35). This is consistent with previous work from
our lab showing that COX-2 is overexpressed in the canine
osteosarcoma stem cells and that inhibition of COX-2 may
be sufficient to inhibit tumour initiation (10). At what times,
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FIGURE 4 | COX-2 regulates cell invasion. (A) CMGD2 and (B) TLM1 cells were transfected with either miRNACOX2-346 or the miRneg negative control with (+) or
without (–) DOX. Invasion potential was determined 48 h after seeding into a transwell chamber assay (QCMTM collagen-based cell invasion assay kit) (p = 0.0004*,
p = 0.0002**).
and in which sub-set of cells, COX-2 expression is required to
promote tumourigenesis is unclear. A disadvantage of working
with the canine model is a lack of the molecular tools to elucidate
the varied roles of COX-2 in tumourigenesis. In this study
we describe the creation of two canine melanoma cell lines
in which COX-2 expression can be reversibly down-regulated
by a doxycycline-inducible miRNA that targets the COX-2
transcript. The vector used has a red fluorescent reporter to allow
investigators to assess the feasibility of the inducible system for
the cell line specific applications. The ability to reversibly knock-
down COX-2 gene expression allows for reversible manipulation
of COX-2 expression at any time during tumour progression,
in contrast to conventional COX-2 gene disruption strategies
which permanently eliminate global COX-2 expression at all
times. Here we utilised this system to show that, in the context of
canine melanoma, COX-2 is required for cellular proliferation,
migration and invasion. Previous studies, consistent with our
data, have shown that, by immunohistochemical analysis of
COX-2, there is a significant association between COX-2 levels
and the proliferation status of cells within a tumour cell
population (5, 7, 29, 31). Several studies have also revealed the
inhibition of COX-2 by NSAIDs and COXIBs leads to a dose-
dependent reduction in cell proliferation in a range of cancer
cell lines (15, 36–38). Using CMGD2 and TLM1 cells we have
shown that when COX-2 expression is knocked-down there is
a significant decrease in cell proliferation and colony forming
efficiency compared to the negative control. Although COX-2
has been observed to promote cell proliferation by regulating
the activation of downstream oncogenic pathways (39), the
underlying molecular mechanism of COX-2 driving cellular
proliferation remains to be elucidated.
Melanoma is an aggressive and highly metastatic disease
(28). The metastatic process involves the migration of a cell with
tumour-initiating potential from the tumour microenvironment
followed by the subsequent invasion and colonisation of a
secondary site within the body. Here we showed that both the
invasive capacity and migration potential of melanoma cells is
dependent on COX-2. The epithelial-to-mesenchymal transition
(EMT) is a key process involved in acquisition of metastatic
potential in number of different types of cancer, including
melanoma. During EMT of cancer cells, epithelial cells lose
the apical-basal polarity and detach from surrounding cells
and transition to invasive mesenchymal cells, which ultimately
leads to the active entry of cancer cells into circulation (40).
Previous studies have linked COX-2 to the EMT process:
COX-2 overexpression has been associated with upregulation of
mesenchymal markers and downregulation of epithelial markers
(41); and in breast cancer, COX-2 induced production of PGE2
inhibited Smad signalling thereby enhancing EMT progression
and metastasis (42). Moreover, treatment with various COXIBs
led to the reversion of EMT in several cancer cell lines (43, 44).
EMT is a key mediator of cancer stem cell plasticity, where
by non-cancer stem cells can dedifferentiate and acquire stem
cell characteristics, and it is these cells that are responsible for
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FIGURE 5 | Migration of canine melanoma cells is COX-2 dependent. (A) Representative image of a scratch assay of TML1 cells transfected with either
miRNACOX2-346 or the miRneg negative control, treated with 1µg/ml DOX. After 24 h incubation a scratch was made and the gap distance was measured at regular
intervals until the gap closed. (B) Quantification of this data (i) miRneg negative control and (ii) miRNACOX2-346 (p < 0.05*, p < 0.0001**).
metastatic dissemination. Given that COX-2 has been shown to
be overexpressed in cancer stem cells it is interesting to speculate
that COX-2 may maintain the cancer stem cell population by
driving EMT. The presence of cancer stem cells in different
melanoma cell lines and tumours has previously been reported
for humans but not for dogs (45–48). To date an evaluation of the
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role of COX-2 in melanoma stem cell biology has not yet been
undertaken. By extension, future research should address the
mechanistic role that COX-2/PGE2 axis plays in melanoma
biology and determining if pharmacological inhibition
of COX-2 could prevent cancer stem cell survival, EMT
and metastasis.
CONCLUSIONS
Our study provides empirical evidence that COX-2 protein
expression is negatively correlated with a worse prognosis
in canine patients with melanoma. Extensive clinical studies
should be performed to determine the prognostic significance of
COX-2 as a marker of canine melanoma. COX-2 is associated
with almost all stages of tumour development including
tumour initiation, immunosuppression, EMT and metastasis,
which all contribute to therapeutic resistance. This is the first
study to have developed and characterised a canine-specific
DOX-inducible COX-2 miRNA vector. This is a valuable
molecular tool for further understanding the mechanisms
through which COX-2 effects melanoma progression. Here
we have shown that cellular proliferation, invasion and
migration are COX-2 dependent in an in vitro canine
melanoma model. Further studies are required to establish
COX-2 as a bona fide therapeutic target in the treatment of
canine melanoma.
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Supplementary Figure 1 | Panel of negative and positive controls of
immunohistochemistry. (A) Cutaneous melanoma, negative control, Ki-67 marker.
Giemsa counterstain (B) Cutaneous melanoma, positive internal control. Ki-67
staining in the nucleus of epidermal cells. DAB staining of chromogen. Giemsa
counterstain. (C) Cutaneous melanoma, negative control. Melan-A marker.
Giemsa counterstain. (D) Cutaneous melanoma, positive internal control. Melan-A
staining in the cytoplasm of melanocytes cells of the epidermis. DAB staining of
chromogen. Giemsa counterstain. (E) Cutaneous melanoma. Melanoma Antigen
(PNL-2) marker. Giemsa counterstain. (F) Cutaneous melanoma. Melanoma
Antigen (PNL-2) staining in the cytoplasm of melanocytes cells of the epidermis.
DAB staining of chromogen. Giemsa counterstain (G) Mucosal Melanoma,
negative control. COX-2 marker. Giemsa counterstain. (H) Cutaneous melanoma,
positive internal control. COX-2 staining in inflammatory cells. DAB staining to
chromogen. Giemsa counterstain. All images are objective 40x. Scale bar
represents 40µM.
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